✦ LIBER ✦

Cannabidiol – an Innovative Strategy for Graft Versus Host Disease Prevention – an Update of a Phase I/II Study

✍ Scribed by Yeshurun, Moshe; Shpilberg, Ofer; Levy-Assaraf, Maly; Herscovici, Korina; Dreyer, Juliet; Peck, Anat; Israeli, Moshe; Granot, Galit; Gruenewald, Tsipora; Mechoulam, Rafael; Ram, Ron

Book ID: 122230833
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 346 KB
Volume: 20
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2013.12.476

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II Study of Bortezomib Plus Pred

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease

✍ Herrera, Alex F.; Kim, Haesook T.; Bindra, Bhavjot; Jones, Kyle T.; Alyea, Edwin 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 986 KB

Mesenchymal stem cells for treatment of

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

✍ Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roel 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 169 KB

Unrelated allogeneic bone marrow-derived

✍ Kazuo Muroi, Koichi Miyamura, Kazuteru Ohashi… 📂 Article 📅 2013 🏛 Carden Jennings Publishing 🌐 English ⚖ 240 KB

An antithymocyte serum noncytotoxic to m

An antithymocyte serum noncytotoxic to myeloid progenitor cells: Candidate serum for prevention of graft-versus-host disease in bone marrow transplantation

✍ Kenneth A. Foon; John H. Fitchen; Ronald J. Billing; Michael B. Belzer; Paul I. 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 448 KB

Prophylaxis of Graft-Versus-Host Disease

Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study

✍ Parmar, S.; Andersson, B. S.; Couriel, D.; Munsell, M. F.; Fernandez-Vina, M.; J 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 174 KB

Feasibility, Safety and Efficacy of Mara

Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): a Phase I/II Study

✍ R. Reshef; S.M. Luger; A.W. Loren; N.V. Frey; S.C. Goldstein; E.O. Hexner; E.A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB